Bile diversion underlies Roux-en-Y antitumor benefits.
basic_science · Level V
Where this comes from
- Record sourced from PubMed, PMID 40560999.
- Also identified by DOI 10.1126/scitranslmed.adx3814.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
Bile diversion in preclinical Roux-en-Y gastric bypass confers its antitumor effects independently of weight loss (Lässle <i>et al.</i>, this issue).
Medical subject headings
- Bile
- Gastric Bypass